Charlotte, North Carolina (February 9, 2005) - BurnsAdler Pharmaceuticals, Inc. announced today that they have partnered with QOL Medical, LLC for the promotion and distribution of Sucraid® (sacrosidase) Oral Solution in Puerto Rico. Sucraid® is the first and only pharmacologic therapy approved by the FDA as a simple, safe and effective enzyme replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase disease (CSID).
